Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome
Primary Purpose
Myofascial Pain, Myofascial Trigger Point Pain
Status
Enrolling by invitation
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
1% plain lidocaine and 0.25% plain bupivacaine
Sponsored by
About this trial
This is an interventional treatment trial for Myofascial Pain
Eligibility Criteria
Inclusion Criteria:
- Able to speak, read and write English
- Diagnosis of myofascial pain
- Failed conservative therapy or unable to participate in physical therapy
Exclusion Criteria:
- Serious mental illness that may not enable the patient to perceive pain changes
- History of conditions which may present as diffuse pain
Sites / Locations
- Banner University Medical Center Multispecialty Services Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
One to two needle passes
Ten needle passes
Twenty needle passes
Arm Description
Receive 1-2 needle passes for needling at each trigger point
Receive 10 needle passes for needling at each trigger point
Receive 20 needle passes for needling at each trigger point
Outcomes
Primary Outcome Measures
Change in pain intensity
The primary outcome is the length of time patients subjectively report at least 50 percent reduction in pain compared to their baseline following trigger point injections using the Numerical Pain Scale which ranges from 0-10, where 0 = no pain and 10 = the worst possible pain.
Secondary Outcome Measures
Change in Sleep patterns
Change the Pittsburgh Sleep Quality Assessment Questionnaire by at least 30 percent. The Pittsburgh Sleep Quality Assessment Questionnaire has a scale from 0-21. The lower the score, the better the sleep quality.
Perceived Subjective Changes in the Ability to Work, Do Chores, and Exercise.
Changes in abilities of the participants to work, do chores, and exercise by at least 30 percent. This will be assessed using subjective reports from the recruited participants. The participants will be asked to report their perceived changes in their ability to Work, do chores, and exercise. Zero percent indicates no change from baseline. one hundred percent indicates complete resolution of the perceived problem.
Full Information
NCT ID
NCT04732507
First Posted
December 10, 2020
Last Updated
October 3, 2022
Sponsor
University of Arizona
1. Study Identification
Unique Protocol Identification Number
NCT04732507
Brief Title
Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome
Official Title
Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
April 20, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
July 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Arizona
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Myofascial pain is a common condition in which patients may experience severe chronic pain. The source of this pain is typically the soft tissue. Current methods to address myofascial pain include a procedure called Trigger point Injections. This method involves identifying the areas of muscles that are causing the pain. The most common way to perform trigger point injection involves infiltrating the muscle with local anesthetics and then repeatedly passing the numbing needle in and out of the muscles (needling). This procedure is successful for most patients. However, there is great variability in the way needling is done. Some pain physicians perform 1-2 needle passes while other pain physicians may exceed 20 passes. There are currently no guidelines as to the number or amount of needle passes needed to achieve pain control. Furthermore, there is no study or research to shed light on the relationship between the number of needles passes and the degree and duration of pain relief coupled with patients' satisfaction.
This study is proposed to address this gap in knowledge. It is a prospective and randomized clinical trial that follows the standard of care. The investigators will recruit patients from The University-Banner Medical Center at Tucson, Arizona chronic pain clinic who are candidates for trigger point injections. The participants will be randomized into 3 different groups. Group one will receive 2 needle passes per identified trigger point. Group two will receive ten needle passes per identified trigger point. Group three will receive twenty needle passes per identified trigger point.
The investigators will analyze the data to understand the relationship between the number of needles passes and the degree of pain relief, improved functional capacity, and patients' satisfaction.
Detailed Description
Chronic pain affects over 100 million Americans with an annual cost of about $600 billion/year. Almost half of the chronic pain conditions are attributed to musculoskeletal conditions.
Musculoskeletal pain is typically identified with palpation over tender areas initially identified by the patient and then verified by the physician. There are typically areas of muscles that when palpated, pain is experienced by the patient. These points are known as Trigger Points. There are several ways to manage trigger points. Muscle relaxers are the most common pharmacological approaches to manage trigger points, but they can cause significant sedation for patients. Some non-pharmacological methods such as physical therapy may also provide some relief of musculoskeletal pain. However, physical therapy requires active participation from patients in addition to lifestyle modifications. Additionally, for some patients, the severity of their musculoskeletal pain precludes them from effectively participating in physical therapy. For those patients, trigger point injections may provide enough relief to effectively participate in physical therapy. Trigger point injections is a procedure where an area identified is first injected with a local anesthetic then the needle is repeatedly inserted in and out (needling). The exact mechanism of action is not clear, but it does provide significant relief for most patients with musculoskeletal pain. Interestingly enough, while trigger point injections are a very common procedure and are performed by almost all pain physicians, there is great variability in the method it is performed. There is currently no clear guidance as to how light or intense the "needling" aspect of the procedure should be. On one end of the spectrum, some pain physicians perform 1-2 needle passes. On the opposite end of the spectrum, other pain physicians perform 40-50 or more needle passes. The literature is not very clear as to which is better in terms of the number of passes. In fact, the range of passes from one study to the other may account for some inconsistencies of the outcome associated with performing trigger point injections. The greater the number of passes, the greater the risk for possible side effects. On the other hand, pain relief may be directly proportional to the number of passes. The investigators currently do not have such information. The purpose of this study is to understand the relationship between the intensity of the needling aspect of trigger point injections and pain relief. In this study, patients will undergo the typical standard of care treatment for musculoskeletal pain with randomization regarding the number of passes during needling. The investigators will evaluate the patient response using paper surveys over 2 months following their procedures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myofascial Pain, Myofascial Trigger Point Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Model Description
Depending on assignment, one group will receive 1-2 needle passes at each trigger point, the other will receive 10 and the third will receive 20.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
One to two needle passes
Arm Type
Active Comparator
Arm Description
Receive 1-2 needle passes for needling at each trigger point
Arm Title
Ten needle passes
Arm Type
Active Comparator
Arm Description
Receive 10 needle passes for needling at each trigger point
Arm Title
Twenty needle passes
Arm Type
Active Comparator
Arm Description
Receive 20 needle passes for needling at each trigger point
Intervention Type
Combination Product
Intervention Name(s)
1% plain lidocaine and 0.25% plain bupivacaine
Intervention Description
A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.
Primary Outcome Measure Information:
Title
Change in pain intensity
Description
The primary outcome is the length of time patients subjectively report at least 50 percent reduction in pain compared to their baseline following trigger point injections using the Numerical Pain Scale which ranges from 0-10, where 0 = no pain and 10 = the worst possible pain.
Time Frame
60 days
Secondary Outcome Measure Information:
Title
Change in Sleep patterns
Description
Change the Pittsburgh Sleep Quality Assessment Questionnaire by at least 30 percent. The Pittsburgh Sleep Quality Assessment Questionnaire has a scale from 0-21. The lower the score, the better the sleep quality.
Time Frame
60 days
Title
Perceived Subjective Changes in the Ability to Work, Do Chores, and Exercise.
Description
Changes in abilities of the participants to work, do chores, and exercise by at least 30 percent. This will be assessed using subjective reports from the recruited participants. The participants will be asked to report their perceived changes in their ability to Work, do chores, and exercise. Zero percent indicates no change from baseline. one hundred percent indicates complete resolution of the perceived problem.
Time Frame
60 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Able to speak, read and write English
Diagnosis of myofascial pain
Failed conservative therapy or unable to participate in physical therapy
Exclusion Criteria:
Serious mental illness that may not enable the patient to perceive pain changes
History of conditions which may present as diffuse pain
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohab Ibrahim, Md., Ph.D
Organizational Affiliation
University of Arizona
Official's Role
Principal Investigator
Facility Information:
Facility Name
Banner University Medical Center Multispecialty Services Clinic
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85711
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome
We'll reach out to this number within 24 hrs